TABLE 1.
Isolates tested and drug | MIC (μg/ml) for the indicated ATCC reference strain
|
Type II clinical isolates
|
|||||||
---|---|---|---|---|---|---|---|---|---|
Type II BAA-849 | M. peregrinum 35755 |
M. senegalense
|
No. tested | MIC (μg/ml)a
|
|||||
13781 | 35796T | Range | 50% | 90% | Mode | ||||
Group A (all isolates) | |||||||||
Amikacin | 0.5 | ≤0.25 | ≤2 | ≤1 | 43 | ≤0.25-4 | ≤1 | ≤2 | ≤1 |
Cefoxitin | 16 | 8 | 16 | 16 | 43 | 4-32 | 16 | 32 | 16 |
Ciprofloxacin | 0.25 | ≤0.063 | 1 | 0.5 | 43 | 0.25-1 | 0.5 | 1 | 0.5 |
Doxycycline | 1 | ≤0.25 | ≤0.12 | ≤0.12 | 42 | ≤0.12-1 | ≤0.25 | 0.5 | ≤0.12 |
Imipenem | 2 | ≤0.5 | 4 | 2 | 42 | 0.25-4 | 1 | ≤4 | 1 |
Sulfamethoxazole | 64 | ≤1 | 16 | 16 | 42 | ≤1-64 | 8 | 32 | 8 |
Tobramycin | 8 | 2 | 4 | 8 | 43 | 1-8 | 4 | 8 | 4 |
Group B (selected isolates) | |||||||||
Clarithromycin | 0.5 | ≤0.12 | 0.5 | 0.25 | 30 | ≤0.12-2 | 0.25 | 1 | ≤0.25 |
Levofloxacin | 0.5 | ≤0.12 | 0.5 | 0.5 | 23 | ≤0.12-1 | 0.5 | 1 | 0.5 |
Linezolid | 4 | ≤2 | 4 | ≤2 | 30 | 1-8 | 2 | 8 | ≤2 |
Gatifloxacin | 0.25 | ≤0.06 | 0.25 | 0.12 | 24 | ≤0.12-0.5 | ≤0.12 | 0.25 | ≤0.12 |
Meropenem | 1 | 2 | 8 | 4 | 24 | ≤0.5-4 | 2 | 4 | 1, 2, 4 |
50% and 90%, MICs at which 50 and 90% of isolates are inhibited, respectively.